Release Date: November 25, 2009
Expiration Date: November 24, 2010
Media
Slides with interactive questions. Printable PDF also available.
Target Audience
This activity is intended for hematologists, oncologists, oncology nurses, oncology/specialty
pharmacists, and others who are involved with the care of patients with metastatic
colorectal cancer (mCRC).
Statement of Need
Colorectal cancer (CRC) is the third most commonly diagnosed malignancy and the
second leading cause of cancer death in the United States. Approximately 149,000
new cases are diagnosed each year. At the time of presentation, about 20% of patients
with CRC will have metastatic disease. Cure at this stage is rarely possible, although
some patients whose metastases are limited (especially if to the liver or lung)
may be "cured" by surgical means. For most sufferers of mCRC, however, treatment
is palliative, offering prolonged survival, improvement in symptoms, and enhanced
quality of life.
Educational Objectives
On completion of this activity, participants should be able to:
- Evaluate and assess current findings in the management of mCRC
- Identify current first-line therapies, both chemotherapeutic and biologic agents,
and practices in mCRC
- Tailor a therapeutic regimen to meet the needs of the individual patient with mCRC
- Employ select strategies to minimize exposure to ineffective therapies and their
toxicities
Faculty Information and Disclosures
Neal P. Christiansen, MD click
here for bio
Assistant Professor of Medicine
Medical University of South Carolina
Division of Hematology/Oncology
Charleston, South Carolina
Faculty Biography:
Dr Christiansen graduated from Washington University School of Medicine in St. Louis,
and did his internal medicine training at Michael Reese Hospital and Medical Center
in Chicago. From 1984 until 1986 he completed his medical oncology training at the
University of Minnesota. Afterward he was on the faculty at the University of Minnesota,
the University of Tennessee in Memphis and at Roswell Park Cancer Institute in Buffalo,
NY before moving to Columbia, SC, in August 1996. From 1999 he was practicing at
South Carolina Oncology Associates, and in April 2009 he took a position as Assistant
Professor of Medicine, Division of Hematology/Oncology at the Medical University
of South Carolina. Dr Christiansen was named to "Best Doctors in America" in 1998.
Disclosures:
Dr Christiansen has received consultancy fees from sanofi-aventis and Genentech.
Off-label use of cetuximab (in patients in whom irinotecan has not failed) and bevacizumab
(continuing after first-line therapy) will be discussed in this presentation.
Conflict resolution: This presentation has been peer reviewed for evidence base
and fair balance.
Instructions
To receive a statement of credit, you must:
- Review the content of the activity.
- Successfully complete the post-test (70% or higher).
- Complete the evaluation at the end of the activity.
Your statement of credit will be issued immediately upon successful completion of
the post-test and submission of the evaluation.
Accreditation Statement
This activity has been planned and implemented in accordance with the Essential
Areas and policies of the Accreditation Council for Continuing Medical Education
(ACCME) through the joint sponsorship of the University of California, Irvine School
of Medicine (UCI) and Center of Excellence Media, LLC. The University of California,
Irvine School of Medicine is accredited by the ACCME to provide continuing medical
education for physicians.
Credit Designation Statement
The University of California, Irvine School of Medicine designates this educational
activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians
should only claim credit commensurate with the extent of their participation in
the activity. This activity is complimentary.
General Disclosure Statement
It is the policy of the University of California, Irvine School of Medicine and
the University of California CME Consortium to ensure balance, independence, objectivity,
and scientific rigor in all CME activities. Full disclosure of conflict resolution
will be made in writing via handout materials or syllabus.
Bonnie Carroll, Director, CME, UC Irvine School of Medicine, has no financial or
other relationship to products or devices with commercial interests related to the
content of this CME/CE activity.
Center of Excellence Media, LLC: The planners and managers have nothing to disclose
related to the content of this activity.
Erica Johansson, RN, Astute CE, LLC, has nothing to disclose related to the content
of this activity.
Dr. Randall F. Holcombe, University of California, Irvine School of Medicine, peer-reviewed
the content for evidence base and fair balance. Dr Holcombe has no real or apparent
conflicts of interest related to this activity.
Conflict resolution: This presentation has been peer reviewed for evidence base
and fair balance.
This activity is in compliance with California Assembly Bill 1195, which requires
continuing medical education components to include curriculum in the subjects of
cultural and linguistic competency. For specific information regarding Bill 1195
and definitions of cultural and linguistic competency, please visit the CME Web
site at http://www.cme.uci.edu.
 
This activity is supported by an educational grant from Genentech BioOncology.
Software Requirements
PC
Internet Explorer 5.5 or greater
Firefox
Windows 2000 or greater
Sound Card & Speakers
800 x 600 Minimum Monitor Resolution
(1024 x 768 Recommended)
Flash Player Plug-in (9.0 or later)
* Adobe
Acrobat Reader
*Required to view Printable PDF Version
Mac OS 10.2.8
Safari
Firefox
Sound Card & Speakers
800 x 600 Minimum Monitor Resolution
(1024 x 768 Recommended)
Flash Player Plug-in (9.0 or later)
* Adobe
Acrobat Reader
In collaboration with 
|
